# Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct05950516` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05950516](<https://clinicaltrials.gov/study/NCT05950516>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05950516

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 478 participants.

## Technical summary

Registry record NCT05950516. Randomized; no masking; primary purpose treatment. Start 2023-07-10 (anticipated); primary completion 2024-11-24 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 478 participants (planned count; ClinicalTrials.gov record NCT05950516, source copy `cardio:ctgov-nct05950516-2023-07-18`, retrieved 2026-10-26)
- Planned start: 2023-07-10 (anticipated) (ClinicalTrials.gov record NCT05950516, source copy `cardio:ctgov-nct05950516-2023-07-18`, retrieved 2026-10-26)
- Primary completion: 2024-11-24 (anticipated) (ClinicalTrials.gov record NCT05950516, source copy `cardio:ctgov-nct05950516-2023-07-18`, retrieved 2026-10-26)
- Completion: 2025-01-22 (anticipated) (ClinicalTrials.gov record NCT05950516, source copy `cardio:ctgov-nct05950516-2023-07-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05950516, source copy `cardio:ctgov-nct05950516-2023-07-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05950516-2023-07-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Semaglutide
- Intervention (Drug): Semaglutide Pen Injector \[Ozempic\]
- Lead sponsor: Qilu Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Qilu Pharmaceutical Co., Ltd. (`cardio:org-qilu-pharmaceutical-co-ltd`)

## Provenance

Content hash: db6869a134e79b72e85c4948c9cef2ec791518ddb55458f4107de0787fdfc3a7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
